BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-145@catalystbrief.girapphe.com
DTSTAMP:20261118T181548Z
LAST-MODIFIED:20261118T181548Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Xenon Pharmaceuticals Inc. — Azetukalner [May 2027]
DESCRIPTION:Phase 3 primary completion: A Randomized Study of Azetukalner V
 ersus Placebo in Major Depressive Disorder (X-NOVA3).\nSource: https://cli
 nicaltrials.gov/study/NCT07076407\nhttps://catalystbrief.girapphe.com/e/14
 5?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/145?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
